Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vicarious Surgical ( (RBOT) ) has shared an announcement.
On September 12, 2025, Donald Tang resigned from the Board of Directors of Vicarious Surgical Inc., with no disagreements cited regarding the company’s operations, policies, or practices. Following his resignation, Victoria Carr-Brendel was appointed to the Audit Committee, indicating a seamless transition in the company’s governance structure.
The most recent analyst rating on (RBOT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Vicarious Surgical stock, see the RBOT Stock Forecast page.
Spark’s Take on RBOT Stock
According to Spark, TipRanks’ AI Analyst, RBOT is a Underperform.
Vicarious Surgical’s stock score reflects significant financial challenges as a pre-revenue company with high cash burn, offset by a moderately stable balance sheet. Technical analysis indicates bearish sentiment, compounded by valuation challenges due to negative earnings. While the earnings call showed strategic advancements, supply chain delays and NYSE compliance issues pose risks. Successful clinical trials and improved cash management will be critical for future performance.
To see Spark’s full report on RBOT stock, click here.
More about Vicarious Surgical
Average Trading Volume: 31,596
Technical Sentiment Signal: Sell
Current Market Cap: $35.06M
Find detailed analytics on RBOT stock on TipRanks’ Stock Analysis page.